

Effect Of Prednisone On Guillain-Barré Syndrome In HIV Positive Patients

H Foyaca, L Ibañez-Valdes, A Awotedu

Citation

H Foyaca, L Ibañez-Valdes, A Awotedu. *Effect Of Prednisone On Guillain-Barré Syndrome In HIV Positive Patients*. The Internet Journal of Neurology. 2002 Volume 2 Number 1.

Abstract

INTRODUCTION

Neurology is one of these medical disciplines in which many frustrating results due to a lack of proper curative treatment, are seen. However to see patients in progressive recovery from a complete paralysis of their four limbs and, inability to talk, swallow, and breath spontaneously, is very stimulating. It is commonly observed in patients with Guillain-Barré Syndrome (GBS) under early treatment with IV Immunoglobuline and/ or Plasmapheresis, but what is expected for HIV patients with GBS where these facilities are not available? The answer probable is: "depends in what stage of the AIDS these patients are" but without doubt to identify and treat this condition in an early stage will help to our patients to afford further neurological complications in better conditions.

GBS is a acute autoimmune predominant polyradiculoneuropathy with a clinical presentation of flaccid paralysis with areflexia; although hyperreflexia is a controversial symptom in patients with GBS some of them may develop functional corticospinal tract involvement_{2,3}, also variable sensory disturbances including a sensory variant₄ can be seen, and an elevated cerebrospinal fluid protein without pleocytosis is almost pathognomonic. GBS had been viewed as a group of syndromes with several distinctive subtypes these include the principal subtype prevalent in the Western world: Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and others like: Acute motor sensory axonal neuropathy (AMSAN), Acute motor axonal neuropathy (AMAN), Fisher syndrome (FS), and Acute panautonomic neuropathy (APN)₅ which are also characterized by a rapid symmetrical involving of the longest pathways in the periphery often preceded by an antecedent event or trigger, most frequently an infection disease such as: Group A beta-hemolytic streptococcal

infection in Fisher syndrome predominantly₆, HIV/AIDS_{7,8}, cytomegalovirus(CMV), CMV-infected fibroblasts express ganglioside-like epitomes that recognize specifically anti-GM2 antibodies induced by molecular mimicry between GM2 and antigens in CMV infection₉; Human parvovirus B19 infection₁₀;Mycoplasma pneumoniae infection₁₁; West Nile virus infection₁₂; varicella₁₃;Haemophilus influenzae infections can elicit an AMSN₁₄ or an AMAN₁₅ in those patients the recovery seemed to be better than those with GBS and Campilobacter jejuni (C jejuni) infection. C jejuni is the most frequently reported antecedent infection in association with GBS; the pure motor variant of GBS accounts for 10% to 20 % of all cases and is highly associated to C jejuni infections (83%), the mortality rate in this group is also high and apart from more severe course, a more pronounce seasonal preponderance is observed_{16,17}; Epstein-Barr virus infection can also influence on the neurophysiologic classification and clinical features of GBS₁₇.The importance of considering Toxoplasma infection as an etiology of GBS in the transplant setting has been reported₁₈.Herpes simplex infection is a rare antecedent infectious agent in Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis₁₉ and an Acute motor axonal Guillain-Barré syndrome after Salmonella typhirium infection in HIV-AIDS patients with an associated cryptococcal meningitis has been also described recently₂₀. Apart from the association of Guillain-Barré syndrome and before-cited gastroenteritis 16 others has been reported such as: systemic lupus erythematosus₂₀

Hairy cell leukemia after a single course of 2-Chlorodeoxyadenosine₂₁ hepatitis A in pregnancy₂₂ organ transplant patients and bone marrow transplant patients whom have iatrogenically suppressed T-cell function supporting the notion that the humoral immune system is

involved in the pathogenesis of GBS²³ an association between Vogt-Koyanagi-Harada disease and GBS has been also described²⁴

Human immunodeficiency virus (HIV) infection an associated GBS was reported by Thornton CA, Ahmed S, et al in Zimbabwe²⁵ among others^{26 27 28 29} GBS may be due to different pathological substrates and most of health professionals consider that steroid medications does not provide additional benefits, however in places where IV immunoglobuline and plasmapheresis are not available and where the incidence of HIV is extremely high, looking into another way of treatment is mandatory.

METHODS

Patients: Thirty patients fulfilling the diagnostic criteria of GBS were identified prospectively for the study during a three-years period; all patients were studied at Umtata General Hospital which is a terminal hospital of the Former Transkei providing neurology service for 15 peripheral hospital with a population of 6.4 millions of people approximately. Almost all eligible patients had active disease characterized by progressive ascending muscle weakness no beyond four weeks.

An experienced neurologist evaluated all patients, none patients had no previous history of peripheral nerve disease and those with concomitant disease (myelopathy or evidence of central demyelination, hepatitis, Lyme disease, cancer, para proteinemia or Castleman's disease) were excluded; pregnant women, and patients with elevated serum creatinine were also excluded. In all patients for testing the cerebrospinal fluid (CSF), lumbar puncture was done. Because nerves conduction studies were not performed with the same protocol at the same stage of the process, with the same operator with the same uniformity, these results were not included for analysis in this report. We studied patients with almost all variants of GBS with only one common No patients receiving treatment for any disease requiring immunomodulatory agents (IVIg, cyclophosphamide, azathioprine, corticosteroids, tacrolimus, cyclosporine, OKT3, plasma exchange alpha, beta or gamma interferon) within the past six months were admitted to the study.

Although most of the immunomodulatory agents before-mentioned are not available in our region, the authors emphasized on this selection criteria for those patients living near of other most advantage regions. Other inclusion criteria were either no neurotoxic antiretroviral therapy, all patients were antecedent-free HIV – defining illness, and

their HIV was diagnosed at presentation with clinical manifestation of GBS. For this reason, none of the patients were receiving antiretroviral therapy at presentation. Other exclusion criteria included alternative cause for neuropathy (e.g. diabetes mellitus, hereditary neuropathy or vitamin B12 deficiency). Other concomitant treatment with the following medications was prohibited for patients while participating in the study.

STUDY DESIGN

The study was designed as a double-blind, placebo-controlled, randomized trial over a predesigned 3-years period. The patients were assigned to receive 1 mg/Kg/day of prednisone after breakfast or placebo, by computer block-randomization consecutive procedure (without distinguish age group). To preserve the blind, all study medications were prepared by the same people and delivered to female and male neurology rooms staff's nurses enclosed in non-transparent numbered plastic bags. The principal investigator, physicians and staff nurses were unaware of which medication or placebo was administered.

OUTCOME MEASURES

Variations in skeletal muscle strength were assessed with the Modify Medical Research council (MRC) scale in which 0 is the lowest and 10 points, the highest,³⁰ and with the Quantitative Muscle Testing (QMT) assessing, the maximum voluntary isometric contraction. Two trained peoples performed the QMT, they evaluated the same muscle group in all patients (deltoid, biceps brachii, triceps brachii, wrist extensors and flexors, quadriceps femoris and the foot extensors and flexors) and the same evaluation was performed by one of us separately. The primary outcome measures were exchanged in the total MRC and QMT scores from baseline to the end of treatment. Obviously for two different outcome measures used other two control of quality were also done by the same interchangeable peoples and considering for statistic analysis when coincidence. Another of us (FSH) independently evaluated clinically the muscle power considering their ability to holding head and for power of the limbs: 0= no movements, 1=flickering movements, 2=lateral movements (side-to-side), 3=movements against gravity, 4=movements against some resistance, and 5= normal. These results were compared with QMT-MRC findings. Each patient receiving the same supporting treatment and was evaluated throughout the study by the same personnel.

Additional outcome measures included the Hughes

Functional Disability Scale (HFDS) (0=normal; 1=minor symptoms capable of running; 2=able to walk up to 10 meters without assistance but unable to run; 3=able to walk 10 meter with assistance of one person, a walker or a cane; 4=unable to walk; 5=requires assisted ventilation; 6=death).

STATISTICS

Two –sided t.test were used to analyze the primary outcome measure, a change in QMT between baseline and the end of the treatment for both group of patients, secondary outcome measures used a similar approach and included change between baseline QMT and at the end of the treatment alone with changes in ability to holding head. The HFDS was assessed by classifying the patients by categories: better, worse, or no change The Pearson x test was used to compare the functional improvement between the groups. The percentage in the change in the scores obtained in the baseline up to the end of treatment was calculated for the 1) QMT of upper limbs; 2) QMT of lower limbs. Clinical bedside test for power were not include in this analysis for obvious reason.

RESULTS

Figure 2




Figure 1: Efficacy analysis

{image:2}

Efficacy analysis included 15 patients (9 women and 6 men, mean age 51 +_ 20 years, range 16 to 77) treated with prednisone, and 14 (8 women and 6 men, mean age 50 +_ 16 years, range 21 to 71) with placebo.

At baseline: no difference between Group P-treated with

prednisone and group C with placebo (prednisone 7.08 + or - 1.27 versus placebo 7.16 +-1.20 p = 0.54) (table 2) was found. At the end of the treatment, improvement was seen in QMT when comparing group P with group C (mean SE, 0.62 +-0.17 versus - 0.1 +-0.1, 0.74 +-0.26, mean difference +-SE; p=0.006). 74% improved in strength in prednisone group. Patients receiving prednisone showed improvement that increases with time (day 14: prednisone: 0.41 +-0.13 versus placebo 0.08 +-0.7, mean +-SE; mean difference +-SE 0.38 +-0.18; P = 0.054; and day 36: prednisone 0.48 +-0.15 versus placebo 0.02 +-0.13 mean +-SE; mean difference +-SE, 0.45 +-0.23; p = 0.046), Table 1.

Table II: Change, % , _SD of Quantitative Muscle Testing scores in patients randomized to prednisone or placebo

Functional performance was different using the HFDS at day 36 comparing prednisone and placebo group (exact p = 0.016). In the group P, 10 patients improved by at least one functional grade (8 patients by one grade and 2 patients by two grades), whereas no patients in this group regressed in functional capabilities. In contrast, only one patient improved by one grade in the group C; in fact this condition worsened and the rest remained unchanged, measurement muscles strength on the neck musculature showed similar results. Grades of disabilities beyond 36 weeks for this study was not established.

Discontinuation of the treatment was not reported. No follow-up data were available in one patient.

Flow chart of the randomized, controlled trial of prednisone and placebo on GBS in HIV positive patients:

Registered or Eligible Patients: N=30

DISCUSSION

The total QMT, clinical bedside assessment, and HFDS scores at baseline in both groups were similar securing adequacy of randomization. Our report provides documentation that prednisone is effective in untreated GBS in HIV positive patients. Using muscle strength (QMT) as the primary outcome variable we found a highly significant difference between prednisone and placebo. The differences were seen as early as 14 days and the gap between prednisone and placebo groups widened at day 36, as the prednisone group continued to improve and the placebo group stayed the same or worsened. Because it is difficult to measure QMT in functional terms, the HFD, an established measure of efficacy in plasma exchange in Guillain-Barré

syndrome provided a good measure of function for the GBS population under study. In this regard, 10 of the prednisone-treat subjects improved at least one functional grade compared with two subjects in the placebo group. Furthermore, two of the placebo-treated patients lost of functional grade, whereas no patients in the prednisone group regressed.

Recently the boundaries of GBS have expanded, and variations that differ clinically, electro physiologically, or with regard to the CSF albumin-cytology dissociation are recognized. However the designation of these variants as falling within the limits of GBS is made because they retain the others essential features of this syndrome. Benator M and Eastman RW³¹ in 2000 described an human immunodeficiency virus associated pure motor lumbosacral polyradiculopathy in 4 Xhosa-speaking African women with similar clinical an electrophysiological pattern seen in GBS but the presence of the CSF pleocytosis was characteristic, those patients presented early in the course of HIV infection (no acquired immunodeficiency syndrome-defining illness) and preserved CD4 cell counts and negative cytomegalovirus tests. Those patients showed spontaneous recovery.

In our study patients with pure sensory deficit showed better outcome that those with pure motor forms presentation from the subjective point of view, and other combined presentations such as facial diplegia with paresthesia (1case) lower cranial nerve palsies, sensory loss in glove-stockng distribution, albumin-cytologic dissociation with HIV seroconversion (1case), motor and sensory disturbance of the lower limbs and autonomic cardiac dysfunction (2 cases) showed poor response to prednisone therapy in this series.

A patient with generalized hyperreflexia showed on CSF examination an important protein elevation and mild lymphocytosis and did no response to steroids medication probable due to functional corticospinal tract involment how has been described³².

Peripheral nerve disorders are common in individuals infected with HIV³³ our selected HIV patients were confirmed by western blot test and had higher CD4 count (>200), plasma viral RNA load, ultra sensitive viral load assays, Chiron bDNA v.3 Organon Teknika Nucliseno, viral culture, genotypic and phenotypic assays and other virology test are not available yet.

In the Thorton et al 25 series, those patients (GBS)

seropositive (N=16) showed a remarkable difference regarding generalized lymphadenopathy, mechanically ventilated and coexistent CNS disturbances such as: neurosyphilis, transient encephalopathy, and myelopathy compared with seronegative GBS patients. In our series apart from hyperreflexia no other sign of CNS involvement was seen; however the common finding was pleocytosis in the CSF (92%) that can be present in non-proportional quantity with the muscle strength improvement. We had hypothesized also that cell count levels are cytokine related, based in other parallel experience.

A course of corticosteroids was given to 4 HIV seronegative and 9 seropositive patients in Thorton's series 25 but information about their results was not reported.

A cytokine-mediated mechanism has been suggested for HIV-associated distal sensory polyneuropathy (DSP) which is the most debilitating symptom in seropositive patients and can affect up to 50% of AIDS patients,³⁵ to differentiate HIV-DSP from BGS (AIDP) or Sensory GBS recordable sensory action potential can help, but the increased protein level and pleocytosis in CSF is confirmatory.^{36 37}

In 1997, Adnan et al⁸ reported three immunocompromised patients with confirmed GBS, two of them were HIV positive and the third one had cardiac transplantation, was on azathioprine and cyclosporine, other eleven immunosupressed patients (5-post renal + high doses of corticosteroid,^{38 39 40} 3-Hofgkin's disease,⁴¹ 2- cardiac transplant + azathioprine, steroids, and cyclosporine, ⁴² 1-lymphoma + cytarabine, carboplatinum, etoposide, and steroids⁴³) had been previously reported therefore GBS is not a common problem in immunocompromised patients and almost all of HIV-positive patients develop GBS at the beginning of infection before developing AIDS.^{44 45 46 47 48} Hughes⁴⁹ established that different forms of GBS respond to steroid medication als in a different way and that acute forms of inflammatory demyelinating polyradiculopathy do not. Plasma exchange is the first and only treatment that has been proven to be superior to supportive treatment alone in Guillain-Barré syndrome,⁵⁰ (when is available) is good to remaind that several million of peoples in this world with the same writgh to survive, have not to access to that therapeutical approach. It is the first study done on HIV-seropositive patients with associated GBS under treatment with prednisone. Our results justify to use steroids, especially is not other therapeutical way is available. A recommendation that it be used as "first choice treatment" for HIV-Guillain-Barre syndrome must be

examined in comparison with other available therapeutic approaches.

References

1. Asbury AK. New concepts of Guillain-Barré syndrome. *J child Neurol* 2000 MAR; 15 (3):183-91.
2. Oshima Y, Mitsui T, Endo I, Umaki Y, Matsumoto T.: Corticospinal tract involvement of Guillain-Barré syndrome. *Eur Neurol* 2001 Jul;46(1):39-42.
3. Kalita J, Misra UK, Bansal R. Central motor conduction studies in patients with Guillain-Barré syndrome. *Electromyogr Clin Neurophysiol* 2001 Jun; 41(4):243-246
4. Shin J. and et al: Sensory Guillain-Barré syndrome. *Neurology* 2001; 56:82-86.
5. Linderbaum Y, Kissel JT, Mendell JR: Treatment approaches for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. *Neurology Clinics* 2001 Feb; Vol 19 (1):187-204.
6. Yuki N, Hirata K: Fisher's syndrome and group A streptococcal infection. *J. Neurol Sci* 1998;160(1):64-66.
7. Satishchandra P et al: Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96) *India J Med Res* 200 Jan;111:14-23.
8. Adnani IQ, Cook AA, Mishu HP, Krendel DA. Guillain-Barré syndrome in immunocompromised patients; A report of three patients and review of the literature. *Musc Ner* 1997;7:1002-1007.
9. Ang CW, et al.: Cross-reactive antibodies against GM2 and CMV infected fibroblasts in Guillain-Barré syndrome. *Neurology* 200 Apr 11;54(7):1453-1458.
10. Yamaoka Y, et al.: A case of Guillain-Barré syndrome following human parvovirus B19 infection. *Rinsho Shinkeigaku* 2000 May;40(5):471-475.
11. Vinzio S, Andres E, Goichot B, Schlienger JL. Guillain-Barré syndrome and Mycoplasma pneumoniae infection. *Ann Med Interne (Paris)* 2000 Jun; 15(14):309-310.
12. Ahmed S, Libman R, Wesson K, Ahmed F, Einberg K.: Guillain-Barré syndrome: An unusual presentation of West Nile virus infection. *Neurology* 2000 Jul 12;55(1):144-146.
13. Yoshikawa T, et al: Immune response to gangliosides in a case of Guillain-Barré syndrome after varicella. *Arch Dis Child* 200 Aug;83(2):172-173.
14. Oda M, et al.: A case of acute motor sense axonal polyneuropathy after Haemophilus influenzae infection. *Rinsho Shingkeigaku* 2000 Aug;40(8):836-839.
15. Mori M. et.al. Haemophilus influenzae infection and Guillain-Barré syndrome. *Brain* 2000 Oct.;123 (Pt 10):2171-2178.
16. Koningsveld R, et.al. Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean Island Curacao. *Neurology* 2001;56:1467-1472.
17. Hadden RD, et al: Preceding infection, immune factors and outcome in Guillain-Barré syndrome. *Neurology* 2001 Mar 27;56(6):758-765
18. Gonzalez MI, et al: Cerebral toxoplasmosis and Guillain-Barré syndrome after allogeneic peripheral stem cell transplantation. *Transpl Infect Dis* 2000 Sep;2(3):145-149.
19. Yuki N, Susuki K, Odaka M, Hirata K.: Overlapping Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis associated with anti-GC1b IgG antibody after herpes simplex virus infection. *Acta Neurol scan* 2001 Jul 2001;104(1):57-60.
20. Blanche P, et al: Acute motor axonal Guillain-Barré syndrome after Salmonella typhimurium bacteremia and cryptococcal meningitis in AIDS. *J Neurol* 2001 Apr;248(4):334-335.
21. Stahl, Kalischewski P, Orda C, Baum P. et al. Filtration of cerebrospinal fluid for acute demyelinating neuropathy in systemic lupus erythematosus. *Clin Rheumatol* 2000;19(1):61-63.
22. Sarmiento MA, Neme D. et al. Guillain-Barré syndrome following 2-chlorodeoxyadenosine treatments for hairy cell leukemia. *Leuk Lymphoma* 200 Nov;39(5-6):657-659.
23. Breuer GS, Morali G, Finkelstein Y, Halevey J. A pregnant woman with hepatitis A and Guillain-Barré. *J Clin Gastroenterol* 2001 Feb;32(2):179-80.
24. Najman-Vainer J, Levinson RD, Grave MC, et al. An association between Bogt-Koyanagi-Harada disease and Guillain-Barré syndrome. *And J Ophthalmol* 2001 May;131(5):615-619.
25. Thorton CA, Ahmed S, Latif S. et al. Guillain-Barré syndrome associated with human immunodeficiency virus infection in Zimbabwe. *Neurology* 1991;41:812-815.
26. Eidelberg D, Sotrel A, Vogel H, et al. Progressive polyradiculopathy in acquired immunodeficiency syndrome. *Neurology* 1986;36:912-916.
27. Comblath DR, McArthur JC, Kennedy PGE, et al. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type II infection. *Ann Neurol* 1987;21:32-40.
28. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. *Arch Neurol* 1988;45:945-948.
29. Behar R, Wiley C, McCutchan JA. Cytomegalovirus polyradiculopathy in acquired immunodeficiency syndrome. *Neurology* 1987;37:557-561.
30. Brooke MH, Fenichel GM, Mendell JR, et al. Clinical Investigation in Duchenne dystrophy II: determination of power of the therapeutic trials based of natural history: *Muscle Nerve* 1983;6:91-113.
31. Benatar MG, Eastman RW. Human Immunodeficiency Virus-Associated Pure Motor Lumbosacral Polyradiculopathy *Arch Neurol* 2000;57:1034-1039.
32. Oshima Y, Mitsui T, Endo I, et al. Corticospinal tract involvement in a variant of Guillain-Barré syndrome. *Eur Neurol* 2001 Jul;46(1):39-42.
33. The Guillain-Barré syndrome study group. Plasmapheresis and acute Guillain-Barré syndrome. *Neurology* 1985;35:1096-1104.
34. Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestation of the acquired immunodeficiency syndrome (AIDS): experience at VCSF and review of the literature. *J Neurosurg* 1985;62:475-495.
35. Martin C, Solders G, Sonnerborg, Hansson P. Antiretroviral therapy may improve sensory function in HIV- infected patients. *Neurology* 2000;54:2120-2127.
36. Simpson DM, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. *Neurology* 2000;54:2115-2119.
37. Berger JR, Nath, A. Remedies for HIV-associated peripheral neuropathy. *Neurology* 2000;54:2037-2038.
38. Drachman DA, Paterson P, Berlin B, Roguska J: Immunosuppression and the Guillain-Barré syndrome. *Arch Neurol* 1970;23:385-393.
39. Bale LF, Rote NS, Bloomer LC, Bray PF: Guillain-Barré-like polyneuropathy after renal transplant. Possible association with cytomegalovirus infection. *Arch Neurol* 1980;37:784.
40. Palmer BF, Toto RD: Severe neurologic toxicity induced by cyclosporine A in three renal transplant patients. *Am. J Kidney Dis* 1991;18:116-121.
41. Lisak R, Mitchell M, Zwieman B, Orrechio E, Asbury A: Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies. *Ann Neurol* 1977;1:72-78.

42. Baldwin RT, Pierce RR, Frazier OH: Guillain-Barré syndrome after heart transplantation. *J Heart Lung Transplant* 1992;11: 817-819.
43. Ahmed T, Cook P, Feldman E, Coombe N, Puccio C, Mittelman a, et al Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas. *Leukemia* 1994;8:531-534.
44. Hagberg L, Malmvall BE, Svennerholm L, Alestig K, Norkrans G. Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. *Scan J Infect Dis* 1986;18:591-592.
45. Conlon CP: HIV infection presenting as Guillain-Barré syndrome in Lusaka, Zambia. *Trans R Soc Med Hyg* 1989;83:109.
46. Thorton CA, Latif AS, Emmanuel JC. Guillain-Barré syndrome associated with human immunodeficiency virus infection. Zimbabwe. *Neurology* 1991; 41:812-815.
47. Franciotta DM, Brustia L, Minoli L, Bono G, Ceroni M, Parisi A, Melzi d'Eil G. Acute Guillain- Barré syndrome associated with asymptomatic HIV infection. *Acta Neurol* 1992;14:66-70.
48. Griffin JW, Ho TW. Guillain-Barré syndromes, in Johnson RT,Griffin JW (eds); *Current Therapy of Neurologic Disease*. St.Louis, Mosby,1997,p359.
49. Hughes R, Pathogenesis and treatment of inflammatory demyelinating polyneuroradiculopathy. *Acta Neurol Belg* 2000 Sep;100(3):167-170.
50. Raphael JC, Chevret S, Hughes R, Annane D. Plasma exchange for Guillain-Barré syndrome (Cochrane Review). *Cochrane Database Syst Rev* 2001:2CD001798.

Author Information

H. Foyaca

Department of Neurology, Faculty of Health Sciences, University of Transkei

LdeF Ibañez-Valdes

Department of Family Medicine, Faculty of Health Sciences, University of Transkei

A. A. Awotedu

Department of Internal Medicine , Faculty of Health Sciences, University of Transkei